Advanced

Pancreastatin plasma levels in patients with primary hyperparathyroidism

Bergenfelz, A LU ; Luts, L LU ; Jensen, T B and Sundler, F LU (2000) In World Journal of Surgery 24(12). p.83-1579
Abstract

Pancreastatin, a C-terminally amidated peptide derived from chromogranin A, is known to inhibit insulin secretion, pancreatic enzyme release, and gastric acid secretion. It also inhibits parathyroid hormone (PTH) secretion in animals. The physiologic and clinical relevance of pancreastatin in humans, however, is not known. Because pancreastatin has been found in parathyroid adenomas, we investigated the plasma levels in patients with primary hyperparathyroidism (pHPT). Thirteen patients operated on for solitary parathyroid adenoma were investigated. Plasma levels of pancreastatin and serum levels of ionized calcium and intact PTH were measured before and 6 weeks after operation. In 10 patients the levels were also monitored before and... (More)

Pancreastatin, a C-terminally amidated peptide derived from chromogranin A, is known to inhibit insulin secretion, pancreatic enzyme release, and gastric acid secretion. It also inhibits parathyroid hormone (PTH) secretion in animals. The physiologic and clinical relevance of pancreastatin in humans, however, is not known. Because pancreastatin has been found in parathyroid adenomas, we investigated the plasma levels in patients with primary hyperparathyroidism (pHPT). Thirteen patients operated on for solitary parathyroid adenoma were investigated. Plasma levels of pancreastatin and serum levels of ionized calcium and intact PTH were measured before and 6 weeks after operation. In 10 patients the levels were also monitored before and 60 minutes after adenoma excision. The adenomas were investigated for pancreastatin immunoreactivity by immunocytochemistry. The median weight of the excised parathyroid adenoma was 0.64 g (range 0.07-2.00 g). Cells displaying pancreastatin immunoreactivity were present in all adenomas examined and varied in number and immunostaining intensity among and within the adenomas. Intraoperatively, after adenoma excision the levels of PTH and pancreastatin declined (p < 0.01), whereas the levels of ionized calcium did not change (p = 0.96). At the 6-week follow-up the levels of ionized calcium and PTH had decreased compared to the preoperative levels (p < 0.01), and all patients were normocalcemic. In contrast, the pancreastatin levels were not changed (14.5 +/- 6.1 pmol/L preoperatively vs. 12.8 +/- 11.2 pmol/L 6 weeks postoperatively; p = 0.12). In patients with pHPT, pancreastatin is likely to be produced by the parathyroid adenoma. The changes in pancreastatin levels immediately after surgery warrant further investigation.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adenoma, Adult, Aged, Aged, 80 and over, Chromogranin A, Female, Humans, Hyperparathyroidism, Immunohistochemistry, Male, Middle Aged, Pancreatic Hormones, Parathyroid Neoplasms, Regression Analysis, Statistics, Nonparametric, Journal Article, Research Support, Non-U.S. Gov't
in
World Journal of Surgery
volume
24
issue
12
pages
5 pages
publisher
Springer
external identifiers
  • scopus:0034524701
ISSN
0364-2313
DOI
10.1007/s002680010281
language
English
LU publication?
yes
id
ad99e841-e1f6-487f-8c98-559c6bfd0725
date added to LUP
2017-05-10 17:35:44
date last changed
2017-05-14 04:51:06
@article{ad99e841-e1f6-487f-8c98-559c6bfd0725,
  abstract     = {<p>Pancreastatin, a C-terminally amidated peptide derived from chromogranin A, is known to inhibit insulin secretion, pancreatic enzyme release, and gastric acid secretion. It also inhibits parathyroid hormone (PTH) secretion in animals. The physiologic and clinical relevance of pancreastatin in humans, however, is not known. Because pancreastatin has been found in parathyroid adenomas, we investigated the plasma levels in patients with primary hyperparathyroidism (pHPT). Thirteen patients operated on for solitary parathyroid adenoma were investigated. Plasma levels of pancreastatin and serum levels of ionized calcium and intact PTH were measured before and 6 weeks after operation. In 10 patients the levels were also monitored before and 60 minutes after adenoma excision. The adenomas were investigated for pancreastatin immunoreactivity by immunocytochemistry. The median weight of the excised parathyroid adenoma was 0.64 g (range 0.07-2.00 g). Cells displaying pancreastatin immunoreactivity were present in all adenomas examined and varied in number and immunostaining intensity among and within the adenomas. Intraoperatively, after adenoma excision the levels of PTH and pancreastatin declined (p &lt; 0.01), whereas the levels of ionized calcium did not change (p = 0.96). At the 6-week follow-up the levels of ionized calcium and PTH had decreased compared to the preoperative levels (p &lt; 0.01), and all patients were normocalcemic. In contrast, the pancreastatin levels were not changed (14.5 +/- 6.1 pmol/L preoperatively vs. 12.8 +/- 11.2 pmol/L 6 weeks postoperatively; p = 0.12). In patients with pHPT, pancreastatin is likely to be produced by the parathyroid adenoma. The changes in pancreastatin levels immediately after surgery warrant further investigation.</p>},
  author       = {Bergenfelz, A and Luts, L and Jensen, T B and Sundler, F},
  issn         = {0364-2313},
  keyword      = {Adenoma,Adult,Aged,Aged, 80 and over,Chromogranin A,Female,Humans,Hyperparathyroidism,Immunohistochemistry,Male,Middle Aged,Pancreatic Hormones,Parathyroid Neoplasms,Regression Analysis,Statistics, Nonparametric,Journal Article,Research Support, Non-U.S. Gov't},
  language     = {eng},
  number       = {12},
  pages        = {83--1579},
  publisher    = {Springer},
  series       = {World Journal of Surgery},
  title        = {Pancreastatin plasma levels in patients with primary hyperparathyroidism},
  url          = {http://dx.doi.org/ 10.1007/s002680010281},
  volume       = {24},
  year         = {2000},
}